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growth factor II receptor (M6P/IGF2R), a multifunctional protein,
plays a central role in intracellular targeting of lysosomal
enzymes and control of insulin-like growth factor II (IGF-II) bio-
activity. Importantly, the gene encoding this receptor is fre-
quently inactivated in a wide range of malignant tumors
including hepatocellular carcinomas. Thus, M6P/IGF2R is consid-
ered a putative liver tumor suppressor. The aim of this study was
to establish the impact of the receptor on the invasive properties
of liver cells.
Methods: Reconstitution experiments were performed by
expression of wild type and mutant M6P/IGF2R in receptor-
deﬁcient FRL14 fetal rat liver cells. RNA interference was used
to induce M6P/IGF2R downregulation in receptor-positive
MIM-1–4 mouse hepatocytes.
Results:We show that the M6P/IGF2R status exerts a strong
impact on the invasiveness of tumorigenic rodent liver cells.
M6P/IGF2R-deﬁcient fetal rat liver cells hypersecrete lysosomal
cathepsins and penetrate extracellular matrix barriers in a
cathepsin-dependent manner. Forced expression of M6P/IGF2R
restores intracellular transport of cathepsins to lysosomes and
concomitantly reduces the tumorigenicity and invasive potential
of these cells. Conversely, M6P/IGF2R knock-down in receptor-
positive mouse hepatocytes causes increased cathepsin secretion
as well as enhanced cell motility and invasiveness. We alsoJournal of Hepatology 20
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RNA; siRNA, short interfering RNA.for the anti-invasive properties of M6P/IGF2R, whereas the capac-
ity to bind IGF-II is dispensable for the anti-invasive activity of
the receptor in liver cells.
Conclusions:M6P/IGF2R restricts liver cell invasion by prevent-
ing the pericellular action of M6P-modiﬁed proteins.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Liver cancer represents worldwide one of the most frequent
malignancies [1]. Hepatocellular carcinomas (HCCs) are the most
common primary liver tumors. Although many improvements
have been made in terms of diagnosis and treatment, HCCs are
associated with poor clinical prognosis [2]. Aggressive HCCs have
the capacity to penetrate extracellular matrix (ECM) barriers and
spread into the surrounding parenchyma, leading to intrahepatic
metastasis and portal venous invasion [3].
Different proteinases are involved in the breakdown of ECM
components during tumor invasion and metastasis, including
plasminogen activators, matrix metalloproteinases, and cathep-
sins [4–6]. Hepatocytes are known to produce substantial
amounts of the lysosomal proteinases cathepsin B, cathepsin D,
and cathepsin L [7]. As typical for lysosomal enzymes, the N-gly-
can moieties of cathepsins are modiﬁed during their biosynthesis
with mannose 6-phosphate (M6P) residues which permit interac-
tion with the main lysosomal sorting receptors, the 300-kDa
mannose 6-phosphate/insulin-like growth factor II receptor
(M6P/IGF2R) and the 46-kDa mannose 6-phosphate receptor
(MPR46) [8].
M6P/IGF2R is a multifunctional receptor involved in (a) trans-
port of newly synthesized M6P-tagged lysosomal proteins from
the Golgi network to lysosomal compartments, (b) endocytosis
of extracellular M6P-tagged lysosomal enzymes, (c) proteolytic
activation of transforming growth factor b, and (d) regulation of
the bioavailability of IGF-II [8–10]. To perform all these important
functions, the receptor depends on multiple ligand-binding sites.12 vol. 57 j 337–343
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Fig. 1. M6P/IGF2R status of FRL14 cells. Membrane protein extracts (40 lg) of
FRL14, FRL14/IGF2R wt, and FRL19 cells were subjected to SDS–PAGE and then
immunoblotted with anti-M6P/IGF2R antibodies. The migration positions of
selected molecular mass standards are indicated.
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For some M6P/IGF2R ligands, the receptor domains accommodat-
ing the respective binding sites have been identiﬁed. Further-
more, point mutations have been described which speciﬁcally
interfere with the interaction of the receptor with IGF-II or
M6P-tagged proteins [11–14].
Several lines of evidence support the hypothesis that loss of
M6P/IGF2R function is associated with liver tumor progression.
The gene encoding M6P/IGF2R has been shown to undergo fre-
quent loss of heterozygosity in human HCCs and adenomas, with
concomitant inactivating mutations in the remaining allele
[15,16]. It has been demonstrated that the receptor gene is lost
early in liver tumorigenesis, which suggests that loss of M6P/
IGF2R may represent an initiation event [17]. Given this clinical
signiﬁcance, it comes as a surprise that the impact of the M6P/
IGF2R status on the properties of hepatocytes and HCC cells has
not yet been ﬁrmly established. However, studies in choriocarci-
noma and breast cancer cells have demonstrated that a decrease
in M6P/IGF2R expression enhances tumor cell growth [18,19],
whereas overexpression of the receptor causes the opposite effect
[20,21].
Experiments in transgenic mice have indicated that the anti-
tumorigenic properties of M6P/IGF2R could be linked to its
capacity to downregulate the biological activities of IGF-II [22].
However, other studies indicate that failure to express M6P/
IGF2R may result in an increase of the proteolytic load in the per-
icellular environment and thus enhance the invasive capacity of
tumor cells [23–25]. Thus, it seems that multiple M6P/IGF2R
ligands play a role in tumor formation and metastasis, possibly
in a tissue-speciﬁc manner. In this study, we have now assessed
the impact of M6P/IGF2R on the growth, motility and invasive-
ness of liver cells.Materials and methods
A detailed account of the methodology used in this study can be found in the Sup-
plementary Materials and methods.Results
FRL14 cells display features typical for early-stage fetal hepatocytes
There is now compelling evidence to suggest that in some liver
pathologies HCCs derive from liver stem/progenitor cells or
immature hepatoblasts. Hence, HCC cells often more closely
resemble fetal than adult hepatocytes in terms of their gene
expression pattern [26]. To permit detailed studies on a cellular
level, substantial efforts have been undertaken to establish trans-
formed hepatocyte-like cell lines from fetal rat liver of different
gestational stages. One such cell line, FRL19, has been previously
derived from a prenatal rat liver at day 18.5 of gestation and
shown to express several hepatocyte markers, including the
late-onset enzymes tyrosine aminotransferase and alpha-gluta-
thione S-transferase [27,28]. We have now generated a cell line
derived from day 13.5 fetal rat hepatocytes. The morphology of
these FRL14 cells reﬂects their origin from the hepatocyte line-
age. Furthermore, FRL14 cells express early-stage hepatocyte
markers such as transferrin, while late-onset genes are not
expressed (Supplementary Fig. 1).338 Journal of Hepatology 201In vitro invasion of M6P/IGF2R-deﬁcient FRL14 cells is strongly
inhibited by cysteine cathepsin inhibitors
FRL14 cells are capable of migrating across ECM barriers as
typical for malignant cancer cells. Since such invasive properties
frequently depend on ECM proteolysis, the contribution of
matrix-degrading proteinases to the invasive potential of FRL14
cells was assessed by invasion assays performed in the presence
of different synthetic and endogenous proteinase inhibitors (Sup-
plementary Fig. 2). The strongest effect was caused by the general
lysosomal cysteine proteinase inhibitor E-64 (60% reduction).
Inhibition of FRL14 invasion by the more selective E-64 derivative
CA-074 (40%) and the matrix-metalloproteinase inhibitor
GM6001 (46%) was less pronounced. When the efﬁcacy of phys-
iological proteinase inhibitors was tested, it was found that the
potent serine proteinase inhibitor aprotinin had a much weaker
effect on cell invasion (22% reduction) than the cysteine protein-
ase inhibitor cystatin C (49% reduction). We have earlier observed
a similar proteinase inhibition proﬁle for the invasive properties
of M6P/IGF2R-deﬁcient murine squamous cell carcinoma cells
[25]. When FRL14 extracts were immunoblotted with antibodies
recognizing rat M6P/IGF2R, it became evident that these cells
lack expression of the receptor (Fig. 1).
Ectopic expression of M6P/IGF2R restores the intracellular retention
of lysosomal enzymes and decreases the invasive potential of FRL14
cells in vitro
Receptor-deﬁcient FRL14 cells were stably transfected with
human wild type M6P/IGF2R cDNA to assess the impact of the
M6P/IGF2R status on their cellular properties. Two clones were
selected for further studies, FRL14/IGF2R wt-1 and FRL14/IGF2R
wt-2. By comparison with receptor-positive HeLa human cervical
carcinoma cells, the M6P/IGF2R content of FRL14/IGF2R wt-1 and
FRL14/IGF2R wt-2 cells was estimated to be 2.5 and 2.1 pmol/mg
total cell protein, respectively (Supplementary Table 1). Hence,
the receptor level of the selected clones was within the physio-
logical range [29]. The subcellular localization of M6P/IGF2R
was assessed by immunoﬂuorescence microscopy. As expected,
the ectopically expressed receptor was found to reside in the
Golgi apparatus (Supplementary Fig. 3).2 vol. 57 j 337–343
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Fig. 2. M6P/IGF2R reduces lysosomal enzyme secretion and Matrigel invasion
by FRL14 cells. (A) Two clones of M6P/IGF2R-expressing FRL14 cells (IGF2R wt-1
and IGF2R wt-2) as well as parental and mock-transfected cells were incubated
for 24 h with or without 10 mM NH4Cl prior to determination of b-N-acetylhex-
osaminidase (HEX) activity in cell lysates and media. The secretion levels are
presented as means ± SEM of 4–9 independent experiments. ⁄⁄⁄p <0.001 com-
pared to mock-transfected cells. (B) Microsomal extracts of IGF2R wt-1 and
parental cells (C; 20 lg total protein) and medium corresponding to 20 lg (M1)
and 100 lg (M2) total microsomal protein were subjected to SDS–PAGE and then
immunoblotted with antibodies to cathepsin B (CB) and cathepsin D (CD). proCB/
proCD, procathepsin B/D; scCB/scCD, mature single-chain cathepsin B/D. (C)
Invasion assays of IGF2R wt-1, parental and mock-transfected FRL14 cells using
10% FBS as chemoattractant. Data are presented as means ± SEM of 4 independent
experiments. (D) Wound healing assays of IGF2R wt-2, parental and mock-
transfected FRL14 cells. Data are presented as means ± SD of 3 wounds. Some
error bars have been omitted to avoid obstruction of individual data points.
p = 0.006 compared to parental cells; p = 0.04 compared to mock-transfected
cells. (E) Phase contrast microscopy images of representative wounds at the time
of wounding (0 h) and after incubation for 7 h. Scale bar, 100 lm.
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M6P/IGF2R transports newly synthesized lysosomal enzymes
from the Golgi network to lysosomal compartments [30,31]. To
test the sorting function of the recombinant receptor, we analyzed
the intra- and extracellular activity of the lysosomal marker b-N-
acetylhexosaminidase. Due to the lack of M6P/IGF2R, parental and
mock-transfected FRL14 cells secrete large amounts of b-N-acetyl-
hexosaminidase (39 ± 2% and 51 ± 3%, respectively). Ectopic
expression of human M6P/IGF2R reduced b-N-acetylhexosamini-
dase secretion considerably (FRL14/IGF2R wt-1: 21 ± 2%, FRL14/
IGF2R wt-2: 21 ± 1%). The addition of NH4Cl, a lysosomotropic
base interfering with M6P/IGF2R function [23,32], strongly
increased secretion of b-N-acetylhexosaminidase by FRL14/IGF2R
wt cells. The fact that also both parental and mock-transfected
FRL14 cells showed an increase in b-N-acetylhexosaminidase
secretion upon NH4Cl treatment is probably due to the presence
of MPR46, which also transports lysosomal enzymes in an
NH4Cl-sensitive manner (Fig. 2A). Additionally, the intracellular
transport of cathepsin B and cathepsin D was analyzed. Substan-
tially more procathepsin B was found in the medium of parental
FRL14 cells (38% secretion) as compared to M6P/IGF2R transfec-
tants (16% secretion). For cathepsin D, the difference in secretion
between FRL14/IGF2R wt (21% secretion) and parental FRL14 cells
(27% secretion) was not as pronounced (Fig. 2B). When FRL14/
IGF2R wt cells were subjected to subcellular fractionation by Per-
coll density-gradient centrifugation, 21% of the total b-N-acetyl-
hexosaminidase activity was found in the dense (lysosomal)
fraction, whereas in parental FRL14 cells only 7% of this enzyme
resides in lysosomes (Supplementary Fig. 4). These results dem-
onstrate that ectopic expression of M6P/IGF2R in FRL14 cells leads
to improved intracellular retention of lysosomal enzymes and res-
toration of dense lysosome formation, as previously shown for
receptor-deﬁcient squamous cell carcinoma cells [25].
It has been established that the metastatic properties of tumor
cell lines closely correlate with the ability of the cells to migrate
across Matrigel barriers in vitro [33]. The invasiveness of M6P/
IGF2R-expressing FRL14 cells was found to be reduced by 76%
compared to mock-transfected FRL14 cells, and by 86% compared
to parental FRL14 cells (Fig. 2C). This indicates that M6P/IGF2R is
indeed a potent anti-invasive factor in liver cells.
The motility of parental and receptor-expressing FRL14 cells
was also tested in wound healing assays. Parental FRL14 mono-
layers were highly active in wound closure. After 7 h, all wounds
were fully closed, reﬂecting a mean covered distance of 218 lm.
Mock-transfected FRL14 cells behaved similar to parental cells
(186 lm). In contrast, the wounds of FRL14/IGF2R wt cells
(118 lm) were only about half-closed after this incubation per-
iod. These results show that the presence of M6P/IGF2R strongly
reduces the motility of FRL14 cells in vitro (Fig. 2D and E).
Anchorage-independent proliferation and tumor growth are reduced
by reconstitution of M6P/IGF2R expression in FRL14 cells
Anchorage-independent growth is believed to be a hallmark of
cellular transformation [34]. Soft-agar assays were performed
to test whether FRL14 cells are able to grow in an anchorage-
independent manner. The colony-formation efﬁciency of FRL14/
IGF2R wt cells (81 ± 6 colonies) was considerably lower than that
of parental FRL14 cells (466 ± 23 colonies; p <0.001). In addition,
colonies of FRL14/IGF2R wt cells (0.013 ± 0.002 mm2) were much
smaller than those of FRL14 parental cells (0.037 ± 0.005 mm2;
p = 0.005).Journal of Hepatology 201Furthermore, we tested the ability of FRL14 cells to form
tumors in immunodeﬁcient mice. Contrary to parental FRL14
cells (tumors/injections: 9/9; tumor weight: 13–219 mg; median:
48 mg), tumor formation by FRL14/IGF2R wt cells was reduced
and the tumors were smaller (tumors/injections: 5/9; tumor
weight: 0–100 mg; median: 18 mg). Collectively, our results thus2 vol. 57 j 337–343 339
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Fig. 3. Characterization of M6P/IGF2R mutants expressed in FRL14 cells. (A)
Left panel: membrane extracts of FRL14 cells expressing either wild type or
mutant M6P/IGF2R were incubated with 1 lg biotinylated IGF-II or BSA prior to
addition of avidin–Sepharose beads. Bound material was then subjected to
immunoblotting analysis with anti-M6P/IGF2R antibodies. T, total material
applied to the beads. Right panel: membrane extracts of FRL14 cells expressing
either wild type or mutant M6P/IGF2R were incubated with phosphomannan–
Sepharose beads. After washing with glucose 6-phosphate (G6P), bound proteins
were eluted with 5 mM M6P prior to immunoblotting analysis as above. UB,
unbound material. These experiments were repeated 2–5 times with similar
results. (B) Cells were incubated for 24 h with or without 10 mM NH4Cl prior to
determination of b-N-acetylhexosaminidase (HEX) activity in cell lysates and
media. The secretion levels are presented as means ± SEM of 3–9 independent
experiments. ⁄⁄p <0.01 compared to mock-transfected cells. See Fig. 2A for the
results obtained with cells expressing wild type M6P/IGF2R. (C) Invasion assays of
FRL14 cells expressing either wild type or mutant M6P/IGF2R using 10% FBS as
chemoattractant. Data are presented as means ± SEM of 4 independent experi-
ments. ⁄⁄p <0.01 compared to parental cells.
Research Articleindicate that reconstitution of functional M6P/IGF2R expression
interferes with FRL14 tumor progression.
The relevance of individual ligand-binding sites for the anti-invasive
activity of M6P/IGF2R
M6P/IGF2R is a multifunctional protein with separate binding
sites for IGF-II (domain 11) and M6P-modiﬁed ligands (domains
3 and 9). These binding sites were individually mutated, thus cre-
ating M6P/IGF2R variants either impaired in their interaction
with IGF-II (M6P/IGF2R dom11mut) or M6P (M6P/IGF2R dom3/
9mut). Parental FRL14 cells were then stably transfected with
M6P/IGF2R dom11mut and M6P/IGF2R dom3/9mut cDNAs. The
receptor content of the resulting cell lines was found to be similar
to or slightly above that of FRL14/IGF2R wt cells (Supplementary
Table 1). Indirect immunoﬂuorescence studies revealed that the
subcellular distribution of M6P/IGF2R dom11mut and M6P/IGF2R
dom3/9mut is identical to that of the wild type receptor. This con-
ﬁrms that these mutations do not compromise folding and/or
intracellular targeting of M6P/IGF2R in FRL14 cells.
Wild type and mutant forms of M6P/IGF2R were subjected to
IGF-II and phosphomannan binding assays. As expected, the wild
type receptor was able to bind both ligands. The interaction of
M6P/IGF2R dom11mut with IGF-II was much weaker, while this
mutation did not impede binding of M6P. The M6P binding site
mutant M6P/IGF2R dom3/9mut showed no detectable binding of340 Journal of Hepatology 201M6P, but the ability to interact with IGF-II was preserved
(Fig. 3A and Supplementary Fig. 5).
To study the function of the mutant receptors, the intra- and
extracellular activity of b-N-acetylhexosaminidase wasmeasured.
FRL14/IGF2R dom11mut cells secreted 19 ± 1% of their b-N-acetyl-
hexosaminidase activity, which is similar to cells expressing the
wild type receptor (21% secretion). Both FRL14/IGF2R dom3/9mut
clones secreted a larger proportion of this enzyme (31 ± 1% in
either case), but b-N-acetylhexosaminidase secretion is not as
pronounced as in mock-transfected cells (51%). The addition of
NH4Cl strongly increased the secretion of b-N-acetylhexosamini-
dase by all cell lines tested, including those expressing mutant
receptors (Fig. 3B).
As already observed for FRL14/IGF2R wt cells, the invasive
potential of FRL14/IGF2R dom11mut cells was found to be
strongly diminished compared to parental FRL14 cells (80%
reduction). In contrast, the invasive capacity of FRL14/IGF2R
dom3/9mut cells (14% reduction) was only slightly lower than that
of parental FRL14 cells. This suggests that the ability to bind IGF-
II is dispensable for the anti-invasive activity of M6P/IGF2R in
liver cells. In contrast, the anti-invasive potential of the receptor
appears to be largely based on its ability to interact with M6P-
modiﬁed ligands (Fig. 3C).RNAi-mediated knock-down of M6P/IGF2R increases secretion of
lysosomal enzymes and in vitro invasion of MIM-1–4 cells
RNAi-mediated gene silencing was used to knock-down M6P/
IGF2R expression in receptor-positive MIM-1–4 mouse hepato-
cytes. For transient knock-down studies, MIM-1–4 cells were
transfected with siRNA oligonucleotides targeting Igf2r mRNA.
Densitometric analysis of immunoblots revealed that siRNA
treatment reduced the receptor content of the cells to <5%. This
almost quantitative depletion of endogenous M6P/IGF2R pro-
voked a strong increase in the secretion of b-N-acetylhexosamini-
dase (37 ± 1%) as compared to mock-transfected cells (11 ± 1%).
The invasive potential of siRNA-treated MIM-1–4 cells was also
markedly higher than that of the respective controls, using either
HGF/FBS (1.9-fold increase) or FBS alone (3.8-fold increase) as
chemoattractant (Supplementary Fig. 6).
For permanent receptor knock-down, MIM-1–4 cells were sta-
bly transfected with an M6P/IGF2R-speciﬁc shRNA construct.
Densitometric analysis of immunoblots revealed that the residual
receptor content of the two MIM-1–4/IGF2R shRNA clones chosen
for further studies was <1% as compared with cells transfected
with a control shRNA sequence (Fig. 4A). This goes in hand with
enhanced b-N-acetylhexosaminidase secretion, with MIM-1–4/
IGF2R shRNA cells (line 1: 55%; line 2: 47%) secreting far more
of this lysosomal marker enzyme than parental (7%) and control
cells (16%). Similar observations were made for cathepsin D.
MIM-1–4/IGF2R shRNA cells secreted substantially more of this
lysosomal proteinase (11%) than parental MIM-1–4 cells (1%).
The difference in cathepsin L secretion between MIM-1–4/IGF2R
shRNA and parental cells was less pronounced (87% and 81%,
respectively). NH4Cl treatment resulted in strongly enhanced
b-N-acetylhexosaminidase secretion by parental and control
MIM-1–4 cells. Conversely,MIM-1–4/IGF2R shRNA cells displayed
no further increase in b-N-acetylhexosaminidase secretion upon
addition of NH4Cl (Fig. 4B and C).
Wound healing assays were performed to test the effect of
M6P/IGF2R knock-down on the motility of MIM-1–4 cells.2 vol. 57 j 337–343
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Fig. 4. Effects of stable M6P/IGF2R knock-down on MIM-1–4 cells. (A)
Immunoblot of membrane extracts with antibodies against M6P/IGF2R. GM130
was used as loading control. (B) Cell lysates (C; 20 lg protein) and conditioned
media (M) corresponding to 100 lg (CD) or 4 lg (CL) total cellular protein were
subjected to immunoblotting with antibodies to cathepsin D (CD) or cathepsin L
(CL). proCD/proCL, procathepsin D/L; scCD/scCL, mature single-chain cathepsin D/
L; tcCD/tcCL, mature two-chain cathepsin D/L. (C) Cells were incubated for 24 h
with or without 10 mM NH4Cl prior to determination of b-N-acetylhexosamini-
dase (HEX) activity in cell lysates and media. The secretion levels are presented as
means ± SEM of three independent experiments. ⁄p < 0.05 compared to cells
transfected with control shRNA. (D) Analysis of cell migration using the
monolayer wound healing assay. Data are presented as means of 3–4 wounds.
Error bars have been omitted to avoid obstruction of the individual data points.
IGF2R shRNA-1: p = 0.001 compared to parental cells; p = 0.044 compared to cells
transfected with control shRNA. (E) Phase contrast microscopy images of
representative wounds at the time of wounding (0 h) and after incubation for
8.5 h. Scale bar, 100 lm. (F) Invasion assays using 10% FBS ± 10 ng/ml mouse HGF
as chemoattractant. Data are presented as means ± SEM of ﬁve independent
experiments.
JOURNAL OF HEPATOLOGYMIM-1–4/IGF2R shRNA-1 (mean covered distance: 152 lm) and
MIM-1–4/IGF2R shRNA-2 cells (106 lm) migrated substantially
faster than parental (56 lm) and control cells (78 lm; Fig. 4D
and E). In Matrigel invasion assays performed with HGF/FBS as
chemoattractant, MIM-1–4/IGF2R shRNA-1 cells proved 2.3-fold
more invasive than control cells. MIM-1–4/IGF2R shRNA-1 cellsJournal of Hepatology 201also displayed considerable invasiveness in the absence of exog-
enous HGF, while FBS alone was not sufﬁcient to induce an
appreciable invasive response by control cells (Fig. 4F).Discussion
The gene encoding M6P/IGF2R is frequently mutated during
human and rodent hepatocarcinogenesis [35,36], and some of
these mutations have been shown to inactivate individual recep-
tor functions [12,13]. However, the role of aberrant M6P/IGF2R
expression in HCC formation and progression is still unknown.
In this study, we have assessed the impact of the M6P/IGF2R sta-
tus on the tumorigenic and invasive properties of a receptor-neg-
ative transformed fetal rat liver cell line (FRL14). We have found
that reconstitution of M6P/IGF2R expression in FRL14 cells sup-
presses their tumorigenicity and invasiveness. Furthermore, the
reconstituted cells were less motile and displayed diminished
growth under anchorage-independent conditions. Vice versa,
RNAi-mediated M6P/IGF2R knock-down in receptor-positive
mouse hepatocytes enhanced their migratory and invasive poten-
tial. These results clearly indicate a mechanistic link between
dysfunctional M6P/IGF2R expression and HCC pathogenesis, in
agreement with the tumor-suppressive activities of the receptor
in other forms of cancer [22,37].
In squamous cell carcinoma cells, the anti-invasive activity of
M6P/IGF2R appears to rely on restriction of the pericellular accu-
mulation of M6P-tagged lysosomal proteinases [23–25]. In con-
trast, the anti-invasive effects of M6P/IGF2R in breast cancer
cells have been attributed to decreased IGF-II bioavailability
[21]. Moreover, evidence has been provided that the anti-invasive
properties of M6P/IGF2R in renal carcinoma cells are based on
downregulation of cell-mediated plasminogen activation [38].
In our further studies, we therefore sought to establish the
importance of the individual receptor-ligand interactions for
the anti-invasive activity of M6P/IGF2R in liver cells. We selected
to focus on the capacity of M6P/IGF2R to bind IGF-II and M6P-
containing ligands, since plasmin was found to play only a minor
role in FRL14 cell invasion. Furthermore, IGF-II has been recently
found to enhance the motility of human HCC cells [39]. Structure-
function studies have led to the identiﬁcation of the M6P/IGF2R
domains accounting for binding of IGF-II (domain 11) and M6P
residues (domains 3 and 9). Point mutations within these
domains have been described that selectively interfere with
either interaction [11,14]. The introduction of a mutation known
to reduce the afﬁnity of M6P/IGF2R for IGF-II did not impede its
anti-invasive capacity in FRL14 cells. Conversely, simultaneous
mutation of both M6P-binding sites almost abolished this activity
of the receptor. These results strongly support the notion that the
anti-invasive properties of M6P/IGF2R in liver cells depend on its
interaction with M6P-tagged lysosomal hydrolase(s). Various
lysosomal enzymes have been implicated to participate in the
process of tumor invasion and metastasis. So far, the lysosomal
enzymes most extensively studied in this context are cysteine
cathepsins [6].
Liver tumor cells are known to secrete large amounts of
cathepsins into the surrounding tissue [40]. Therefore, it can be
envisaged that absence of M6P/IGF2R fosters HCC invasion by
exacerbating the secretion of these potent proteinases. Indeed,
we have observed that treatment with cysteine cathepsin inhib-
itors results in substantial reduction of the invasiveness of FRL14
cells. The main cellular targets of these inhibitors in liver cells are2 vol. 57 j 337–343 341
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the two most prominent cysteine cathepsins, cathepsin B, and
cathepsin L [7]. For cathepsin B, it has been shown previously
that this enzyme may exhibit extracellular functions under path-
ophysiological conditions [41]. Compelling evidence for a major
role of cathepsin B and related proteinases in tumor invasion
and metastasis has been derived from pancreatic and breast can-
cer models in cathepsin knock-out mice [42–44]. Furthermore,
transgenic mice overexpressing human cathepsin B have been
found to develop breast cancer metastasis at a much higher rate
than their control littermates [45]. Intriguingly, treatment of
rodents with a broad-spectrum cysteine cathepsin inhibitor has
proven effective in halting breast cancer progression when com-
bined with other chemotherapeutic agents, encouraging consid-
eration of cysteine cathepsins as therapeutic targets in human
cancers [46]. However, it remains to be established whether
pharmacological intervention with tumor-associated cysteine
cathepsin activity holds promise for HCC treatment.Conﬂict of interest
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